Current anticoagulation options in percutaneous intervention: Designing patient-specific strategies

Reviews in Cardiovascular Medicine

Volumn 3, Issue 4, 2002, Pages 176-182

  French, Matthew H ^a   Faxon, David P ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Anticoagulants; Heparin; Low molecular weight heparin; Percutaneous coronary intervention; Thrombin inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBIN III; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BLOOD CLOTTING INHIBITOR; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; FIBRIN DEGRADATION PRODUCT; FONDAPARINUX; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PENTASACCHARIDE; PLASMIN INHIBITOR; REVIPARIN; THROMBIN; THROMBIN INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

BLEEDING; CARDIOVASCULAR PROCEDURES; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW; THROMBOCYTOPENIA;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDIN THERAPY; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; POLYSACCHARIDES; RECOMBINANT PROTEINS;

EID: 0036763638     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary artery stenting and blockade of platelet glyco-protein IIb/IIIa receptors. N Engl J Med. 1999;241:319-327.
2. Weitz J. New anticoagulant strategies: current status and future potential. Drugs. 1994;48:485-497.
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable (Angina). J Am Coll Cardiol 2000;36:970-1062.
4. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: heparin. Circulation. 1994;89:1449-1468.
5. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79:1-17.
6. Duetsch E. The emerging role of low-molecular-weight heparin and antiplatelet therapies in the cardiac catheterization laboratory. Am Heart J. 1999;138:S577-S585.
7. Young J, Kereiakes D. Low-molecular-weight heparin in percutaneous intervention: ready for prime time? ACC Curr J Rev 2002;11:59-64.
8. Montalescot G, Collett JP, Lison L. Effects of various anticoagulant treatments on von Willebrand factors release in unstable angina. J Am Coll Cardiol. 2000;36:110-114.
9. Duetsch E, Cohen M, Radley D, et al. Safety and efficacy of percutaneous procedures in patients receiving subcutaneous enoxaparin for unstable angina: results of ESSENCE trial [abstract]. Circulation. 1998;98:1-563.
10. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year resultd of the ESSENCE study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Col Cardiol. 2000;36:693-698.
11. Zidar JP. Low molecular weight heparin in coronary stenting. Can J Cardiol. 1998; 14(suppl E):35E-39E.
12. Dudek D, Zymek P, Bartus S, et al. Prospective randomized comparison of enoxaparin versus unfractionated heparin for elective percutaneous coronary intervention among ticlopidine-pretreated patients. Przeglad Lekarski. 2001;58:484-486.
13. Ferguson JJ. Nice-3 prospective, open label, non-randomized observation safety study on the combination of LMW heparin with the clinically available GP IIb/IIIa antagonists in 600 patients with acute coronory syndromes. J Invasive Cardiol. 2000;12:E10-E13.
14. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol. 2001;13:272-278.
15. The FRISC II Study Group. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomized multicentre study. Fragmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. 1999;354:708-715.
16. The FRISC Study Group. Low-molecular-weight heparin during instability in coronary artery disease [abstract]. Lancet. 1996;347:561-568.
17. Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001;141:348-352.
18. Preisack, MB, Bonan, R, Meisner, C, et al. on behalf of the REDUCE Study Group. Incidence, outcome, and prediction of early clinical events following percutaneous transluminal coronary angioplasty: a comparison between treatment with reviparin and unfractionated heparin/placebo (result of substudy of the REDUCE trial). Eur Heart J. 1998;19:1232-1238.
19. Hirsh J. Modulating the coagulation cascade: new targets for anthithrombotics and anticoagulants. Am Heart J. 2001;142:S3-S8.
20. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
21. Organization to Assess Strategies for Ischemic Syndromes (OAIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation. 1997;96:769-777.
22. The Direct Thrombin Inhibitor Trialists Collabirative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based in individual patient's data. Lancet. 2002;359:294-302.
23. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995;333:764-769.
24. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complication with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002;143:847-853.
25. Turpie AG, Gallus AS, Hoek JA, for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deepvein thrombosis after total hip replacement. N Engl J Med. 2001;344:619-625.
26. Coussement PK, Bassand JP, Convens C, et al. A synthetic factor-Xa inhibitors (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infraction. The PENTALYSE Study. Eur Heart J. 2001;22:1716-1724.
27. Simoons ML. Pentasaccharide in Unstable Angina (PENTUA) study [abstract]. Abstract presented at: American Heart Association Scientific Session 2001; November 11-14, 2001; Anaheim, CA.